Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights
Newsfile Corp•06/10/2026•18:55 ET
1
Key Highlights
- ➤Fulcrum discontinued pociredir program for sickle cell disease after FDA concerns
- ➤FDA cited malignancy risk across PRC2-targeting interventions, ending pociredir development
- ➤Fulcrum shares fell 51.09% to $3.14 on June 2, 2026
- ➤Kaplan Fox announced an investigation into potential securities violations against Fulcrum
New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
Get started
Create a free account to read the full story.